Avant Technologies Inc. (AVAI: OTCQB) | EQS-News: Avant Technologies to Play Key Role in Ainnova’s U.S. FDA Clinical Study for Its Vision AI Platform
Avant Technologies, Inc. (OTCQB: AVAI) has announced its involvement in Ainnova Tech, Inc.’s upcoming FDA clinical study for its Vision AI platform. Key points include:
- Avant is starting the budgeting process for Ainnova’s FDA interactions.
- Ainnova plans to request a pre-submission meeting with the FDA for guidance on clinical testing for early detection of diabetic retinopathy.
- The goal is to obtain FDA 510(k) clearance to market the technology.
- Ai-nova Acquisition Corp. (AAC), formed by Avant and Ainnova, holds U.S. licensing rights for Ainnova’s technology portfolio.
- Ainnova expects to submit its pre-submission application soon and meet with the FDA in late March/early April 2025.
- Ainnova also plans to seek FDA clearance for four additional algorithms for early detection of various diseases.
- The FDA pre-submission program will help define the regulatory pathway and budget for the clinical study.
This collaboration highlights Avant’s commitment to advancing AI technology in healthcare and Ainnova’s focus on early disease detection using AI.
PressAlchemy helps businesses of all size from startups to established companies to turn their news into headlines. Whether you’re announcing a corporate update, sharing a major project milestone, or launching a new product, press release distribution ensures your story reaches the right audience on top platforms. If you own a business or have a story to share, now’s the time to get noticed.
Expand your reach to 900+ Media Networks, 13.3k Journalists, and a global audience of over a billion users! Get your Press Release or Article featured for your business or story – CLICK HERE.
#Avant #Technologies #AVAI #OTCQB #EQSNews #Avant #Technologies #Play #Key #Role #Ainnova039s #U.S #FDA #Clinical #Study #Vision #Platform
